Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data.
MacGregor
R R
RR
Boyer
J D
JD
Ciccarelli
R B
RB
Ginsberg
R S
RS
Weiner
D B
DB
D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005500:Follow-Up Studies; D015686:Gene Products, env / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D015694:Gene Products, rev / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use*; D054321:rev Gene Products, Human Immunodeficiency Virus
D016915:AIDS Vaccines; D015686:Gene Products, env; D015694:Gene Products, rev; D019444:Vaccines, DNA; D054321:rev Gene Products, Human Immunodeficiency Virus